Am J Transplant, Volume 19, Suppl 3 Archives - Page 108 of 214 - ATC Abstracts

2019 American Transplant Congress
Regulation of Host microRNA Expression by Natural Variants of Epstein Barr Virus (EBV) Latent Membrane Protein 1 (LMP1)
O. Hatton¹, A. Harris-Arnold², A. Hui², E. Maloney², S. M. Krams², O. M. Martinez²
¹Molecular Biology, Colorado College, Colorado Springs, CO, ²Program in Immunology and Department of Surgery, Stanford University, Stanford, CA
*Purpose: Malignancies attributable to EBV, such as post-transplant lymphoproliferative disorder (PTLD), represent 1.8% of global cancer deaths. PTLD occurs in 1-20% of transplant recipients and…
2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
M. Nazzal¹, R. Steele², R. Ray³, N. Phillips², J. Long⁴, R. Ray²
¹Surgery, Saint Louis University, Saint Louis, MO, ²Pathology, Saint Louis University, Saint Louis, MO, ³Internal Medicine, Saint Louis University, Saint Louis, MO, ⁴Comparative Medicine, Saint Louis University, Saint Louis, MO
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…
2019 American Transplant Congress
Impact of Immunosuppressive Drug Withdrawal on Persistent Mixed Chimerism in Recipients of HLA Haplo-Identical Kidney and Hematopoietic Cell Transplants
S. Busque, J. Scandling, R. Lowsky, J. Shizuru, E. Meyer, K. Jensen, A. Shori, R. Hoppe, E. Engleman, S. Strober
Stanford University School of Medicine, Stanford, CA
*Purpose: We assessed the impact of the hematopoietic cell dose and the immunosuppressive drug (IS) withdrawal on the persistence of mixed chimerism after combined HLA…
2019 American Transplant Congress
Normothermic Regional Perfusion of Kidneys: A Single Non-Retrieval Centre Experience
R. Pearson, C. Geddes, M. Clancy, J. Asher
Renal Transplant, Queen Elizabeth University Hospital, Glasgow, Glasgow, United Kingdom
*Purpose: With the aim of safely expanding the pool of usable donors from circulatory death (DCD) there is increasing interest in normothermic regional (NRP) perfusion…
2019 American Transplant Congress
CD19+ Cell Behavior in the 12 Months Following a Single Dose of Rituximab in Patients with Humoral Rejection: Clinical and Histological Outcomes
L. Marino, I. A. Martínez-Juárez, J. R. Marino-Sánchez, J. I. Santander-Velez, F. Zamora, H. Juarez, R. Vazquez, L. Llorente, G. Lima, A. Cohen-Bucay, L. E. Morales-Buenrostro
Nephrology, INCMNSZ, Mexico City, Mexico
*Purpose: Treatment of antibody mediated rejection (ABMR) commonly includes rituximab, but the dose needed is not yet well defined. It has been suggested that a…
2019 American Transplant Congress
Utilization of Donor Kidneys with Acute Kidney Injury in Pediatric Transplantation
C. S. Hwang¹, B. Tanriover², S. Levea², D. Desai¹, V. Ariyamuthu², P. Vagefi¹, M. MacConmara¹
¹Surgery, UT Southwestern, Dallas, TX, ²Medicine, UT Southwestern, Dallas, TX
*Purpose: Donor kidneys that are otherwise healthy with acute kidney injury (AKI) are increasingly used in adult transplant programs. We sought to examine the experience…
2019 American Transplant Congress
Sustained Biologic Response To Neoadjuvant Therapy Predicts Excellent Liver Transplant Outcomes For Locally Advanced Intrahepatic Cholangiocarcinoma
K. E. Lunsford¹, M. Javle², K. Heyne³, R. A. Ali², C. M. Mobley¹, A. Saharia¹, D. W. Victor¹, M. J. Hobeika¹, A. Kasab², R. S. McFadden¹, T. A. Aloia², X. C. Li¹, H. P. Monsour¹, A. O. Gaber¹, A. O. Gaber¹, J. Vauthey², R. M. Ghobrial¹
¹J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³Department of Oncology, Houston Methodist Hospital, Houston, TX
*Purpose: Intrahepatic cholangiocarcinoma (iCCA) is a contraindication for liver transplant (LT), but prior studies limited evaluation to incidental iCCA. We recently reported significant improvement in…
2019 American Transplant Congress
Computational Assessment of T-cell and B-cell Allorecognition to Predict Donor HLA Immunogenicity
H. C. Copley¹, M. Elango¹, V. Kosmoliaptsis²
¹Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospital, Cambridge, United Kingdom, ²University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospital & NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge, Cambridge, UK., Cambridge, United Kingdom
*Purpose: Donor-specific alloantibody (DSA) development after solid-organ transplantation is a major cause of graft loss, and limits future transplant options. We have previously shown that…
2019 American Transplant Congress
Liver Transplant Candidate Attitudes towards Organs from Increased Risk Donors: A Single Center Survey
S. S. Humar, J. Liu, N. Pinzon, D. Kumar, M. Bhat, L. Lilly, N. Selzner
University Health Network, Toronto, ON, Canada
*Purpose: Increased Risk Donors (IRDs) are a significant proportion of the deceased organ donor pool but may be declined by patients on the liver transplant…
2019 American Transplant Congress
Long-Term Survival after Kidney-Pancreas Transplantation: Lessons from World Largest Series of Long-Term Survivors
S. Parajuli, F. Aziz, N. Garg, B. Muth, A. Djamali, R. Redfield, D. Kaufman, J. Odorico, D. Mandelbrot, H. Sollinger
University of Wisconsin, Madison, WI
*Purpose: Since 1983, more than 1700 patients have undergone pancreas transplant, mainly as a simultaneous-kidney-pancreas transplant (SPK) at our center. Forty-eight SPK recipients have pancreas…